Johnson & Johnson Receives FDA Approval for Imaavy to Treat Warm Autoimmune Hemolytic Anemia

The FDA has granted approval for Johnson & Johnson's Imaavy, marking a significant treatment option for patients suffering from warm autoimmune hemolytic anemia. This approval expands therapeutic choices for a rare blood disorder previously lacking targeted therapies.